Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva santé animale - pyriproxyfen, dinotefuran - antiparasitic izdelkov, insekticidi in repelenti, druge ectoparasiticides za lokalno uporabo, pyriproxyfen, kombinacije - mačke - zdravljenje in preprečevanje bolh infestations (ctenocephalides felis) na mačke. ena aplikacija, preprečuje bolh okužbe za en mesec. prav tako preprečuje razmnoževanje bolhe z zaviranjem bolh pojavom v okolju mačka za 3 mesece.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - mačji levkemijo virus rekombinantne canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - aktivna imunizacija mačk, starih 8 tednov ali več, proti mačji levkemiji za preprečevanje vztrajne viremije in kliničnih znakov s tem povezane bolezni. začetek imunosti je bil dokazan 2 tedna po osnovnem cepljenju. trajanje imunitete je eno leto po zadnjem cepljenju.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa  - inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus - imunologija - mačke - za aktivno imunizacijo zdrave mačke devet tednov ali starejši proti mačji panleukopenia in mačji levkemijo virusi in proti bolezni dihal, ki jih povzročajo mačji rhinotracheitis virus, mačji calicivirus in chlamydophila felis.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. na imunski sistem je bil dokazan 1 teden po osnovnem cepljenju za rinotraheitis, kalicivirus in komponento chlamydophila felis. trajanje imunosti je 1 leto po zadnjem (ponovnem) cepljenju.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - v živo mačji panleucopenia virus / parvovirus + live mačji rhinotracheitis virus + live mačji calicivirus + inaktivirano mačji levkemijo virus - mačke - za aktivno imunizacijo mačk, starih osem tednov, proti: mačji kalicivirozi za zmanjšanje kliničnih znakov. mačji virusni rinotraheitis za zmanjšanje kliničnih znakov in virusnega izločanja. mačjo panleukopenijo za preprečevanje levkopenije in zmanjšanje kliničnih znakov. mačje leukemijo za preprečevanje vztrajne viremije in kliničnih znakov s tem povezane bolezni. začetek imunosti: 3 tedne po primarnem cepljenju za komponente panleukopenije in levkemije ter 4 tedne po primarnem cepljenju za komponento virusa kalicivirusa in rinotraheitisa. trajanje imunosti: eno leto po primarnem cepljenju za vse sestavine.

Evropska unija - slovenščina - EMA (European Medicines Agency)

virbac s.a. - očiščen p45 felv-ovojni antigen - inaktivirano virusna cepiva, mačji levkemijo virus, immunologicals za skupin felidae, - mačke - aktivna imunizacija mačk, starih osem tednov, proti mačji levkemiji za preprečevanje vztrajne viremije in kliničnih znakov s tem povezane bolezni.

Evropska unija - slovenščina - EMA (European Medicines Agency)

virbac s.a. - rekombinantni omega interferon mačjega izvora - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. pri mačkah, okuženih s fiv, je bila smrtnost nizka (5%) in na zdravljenje ni vplivala.